<code id='CB56EA22F8'></code><style id='CB56EA22F8'></style>
    • <acronym id='CB56EA22F8'></acronym>
      <center id='CB56EA22F8'><center id='CB56EA22F8'><tfoot id='CB56EA22F8'></tfoot></center><abbr id='CB56EA22F8'><dir id='CB56EA22F8'><tfoot id='CB56EA22F8'></tfoot><noframes id='CB56EA22F8'>

    • <optgroup id='CB56EA22F8'><strike id='CB56EA22F8'><sup id='CB56EA22F8'></sup></strike><code id='CB56EA22F8'></code></optgroup>
        1. <b id='CB56EA22F8'><label id='CB56EA22F8'><select id='CB56EA22F8'><dt id='CB56EA22F8'><span id='CB56EA22F8'></span></dt></select></label></b><u id='CB56EA22F8'></u>
          <i id='CB56EA22F8'><strike id='CB56EA22F8'><tt id='CB56EA22F8'><pre id='CB56EA22F8'></pre></tt></strike></i>

          Home / knowledge / fashion

          fashion


          fashion

          author:explore    Page View:91
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In